NTRBHealthcare · BiotechnologyThe 1 Wall Street analysts covering Nutriband, Inc. hold a median 12-month price target of $15 — +125.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 28 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Nutriband, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (84): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (11): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on NTRB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +125.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Jan 2025 | Noble Capital Markets | Initiates | Outperform | $13 |
| 26 July 2022 | Small Cap Consumer Research | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
NTRB appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Nutriband, Inc. returned −4.2% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 5% of US stocks
Cheaper than 7% of US stocks
Cheaper than 85% of US stocks
Higher than 9% of US stocks
Higher than 16% of US stocks
Higher than 52% of US stocks
Higher than 11% of US stocks
Higher than 87% of US stocks
Higher than 13% of US stocks
Higher than 7% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Nutriband, Inc. has a market value of $72.3M and an enterprise value of $69.1M.
Revenue in the twelve months to 31 July 2026: $1.6M. The latest quarter shrank 29.7% year on year.
Net income over the same four quarters: −$7.0M, a −430.4% net margin.
Free cash flow in the twelve months to 31 July 2026: −$3.6M.
Trailing P/E: −2.3×; forward P/E: −25.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Nutriband, Inc. employs 0 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Nutriband, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Nutriband announced that 272,671 NTRBW warrants were exercised at a strike price of $6.43, generating $1,753,274.53 in proceeds to the company.
Why it matters — The exercise provides NTRB with proceeds from warrant holders, a financing development relevant to shareholders tracking the company’s capital position.
Nutriband filed a new non-provisional patent application to strengthen intellectual property protection for its AVERSA™ transdermal abuse-deterrent technology, which is being developed for opioid and stimulant patches with abuse potential. The technology uses a proprietary aversive-agent coating intended to deter oral abuse and reduce accidental exposure.
Why it matters — NTRB watchers may follow the application as a development in the company’s intellectual property protection for AVERSA™.
Nutriband CEO Gareth Sheridan published a shareholder letter marking the fifth anniversary of the company's October 1, 2021 listing on the Nasdaq Capital Market, reflecting on milestones since the uplisting. The letter was released as AVERSA Fentanyl advances toward an IND filing and the 2021 offering warrants expire as scheduled.
Why it matters — A NTRB watcher would care because the CEO's anniversary letter provides an update on the company's progress since its Nasdaq listing and notes the advancement of AVERSA Fentanyl toward an IND filing.
Nutriband announced that its CEO, Gareth Sheridan, is featured in a new documentary by independent journalist Nick Shirley examining the ongoing opioid crisis in the United States.
Why it matters — The feature raises the profile of Nutriband and its CEO in connection with the opioid crisis, an area relevant to the company's focus.
Nutriband Inc. confirmed that its outstanding warrants (NASDAQ:NTRBW) will expire on September 30, 2026 at 5PM ET as scheduled, without extension or repricing. The company made this announcement on September 22, 2026.
Why it matters — NTRB watchers would care because it clarifies the timeline for the expiration of the company's warrants, confirming there will be no extension or repricing of these instruments.
The 1 Wall Street analysts covering Nutriband, Inc. have a median 12-month price target of $15, with estimates ranging from $15 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Nutriband, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nutriband, Inc. 36 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Nutriband, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (84 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +125.9% from the last close, and Ticker Nerd's factor model ranks Nutriband, Inc. 36 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Nutriband, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NTRB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $15 over the next 12 months.
Nutriband, Inc. returned -4.2% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Nutriband Inc. is a pharmaceutical company focused on the development of transdermal drug delivery products.
The most recent item we track (GlobeNewsWire, 13 Oct 2026): "Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274". Nutriband announced that 272,671 NTRBW warrants were exercised at a strike price of $6.43, generating $1,753,274.53 in proceeds to the company.
Nutriband Inc. is a pharmaceutical company focused on the development of transdermal drug delivery products. The company’s core work centers on abuse-deterrent patch technologies designed to reduce the risk of misuse, diversion, and accidental exposure for drugs with abuse potential, particularly opioids. Its lead development program is AVERSA Fentanyl, alongside additional transdermal products such as AVERSA Buprenorphine and AVERSA Methylphenidate. Nutriband also operates through business segments that include pharmaceuticals and medical devices, supporting both product development and related manufacturing activities. Based in Orlando, Florida, Nutriband serves the healthcare market by advancing patch-based therapies that aim to deliver medications through the skin in a controlled and convenient format.
CEO Mr. Gareth Sheridan · United States · https://www.nutriband.com
